Disease Overview：Diabetes mellitus（DM）
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Classified primarily as Type 1 (autoimmune beta-cell destruction), Type 2 (insulin resistance with progressive beta-cell dysfunction), and gestational diabetes, it affects over 140 million people in China alone. Long-term complications—including diabetic retinopathy, nephropathy, neuropathy, cardiovascular disease, and foot ulcers—underscore the necessity for early diagnosis, individualized glycemic control, lifestyle intervention, and multidisciplinary endocrine management. Modern treatment paradigms emphasize continuous glucose monitoring (CGM), insulin pump therapy, GLP-1 receptor agonists, SGLT2 inhibitors, and structured diabetes education programs delivered by certified endocrinologists and diabetes care teams.
China offers distinct advantages for international patients seeking diabetes management: its top-tier endocrinology centers—many affiliated with universities such as Peking Union Medical College Hospital and Shanghai Jiao Tong University School of Medicine—combine deep clinical expertise with cutting-edge technology, including real-time CGM integration, AI-driven glycemic prediction algorithms, and minimally invasive insulin delivery systems. Clinical outcomes align with global benchmarks: studies from Beijing’s Diabetes Center report >85% HbA1c target attainment in newly diagnosed Type 2 patients after 12 months of protocol-driven care. Crucially, comprehensive outpatient and inpatient diabetes management—including advanced complication screening and surgical interventions like bariatric surgery for obesity-related diabetes—is available at approximately 40–60% lower cost than in the US or Western Europe, without compromising quality or safety standards.
As a dedicated medical tourism agency, we facilitate seamless access to these resources: verifying hospital accreditation, coordinating consultations with board-certified endocrinologists, clarifying all-inclusive pricing upfront, arranging interpreters and accommodation, and providing continuity-of-care support before, during, and after treatment.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Diabetes Mellitus (Endocrinology Department)
Non-Surgical / Conservative / Medication Management
*Target Criteria:* Newly diagnosed T2DM, stable HbA1c <9.0%, no acute complications (DKA/HHS), no severe renal impairment (eGFR ≥30 mL/min/1.73m²).
- •Initial Evaluation & Baseline Labs
- Endocrinology consultation (first visit): $28–$45
- •Tiered Pharmacotherapy (Annual, per drug class)
- SGLT2 inhibitor (e.g., dapagliflozin 10 mg OD): $210–$340 - GLP-1 RA (e.g., semaglutide 0.5 mg SC weekly): $1,180–$1,520 - Basal insulin (e.g., glargine U100, 10 mL vial): $45–$72
- •Structured Education & Monitoring
- Home glucose meter + 100 test strips: $38–$65
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* T2DM ≥5 years, BMI ≥32.5 kg/m² (or ≥27.5 with comorbidities), failed intensive medical therapy (HbA1c >7.5% despite ≥3 agents), no active psychiatric disorder or substance abuse.
- •Metabolic Surgery (Laparoscopic Sleeve Gastrectomy)
- Procedure (including anesthesia, 3-day inpatient stay, surgeon/anesthesiologist fees): $5,800–$8,200
- •Continuous Glucose Monitoring (CGM) Implantation (Professional Use)
Special / Complex Condition Management
- •Diabetic Ketoacidosis (DKA) Admission (72-hour stabilization)
- •Advanced CKD (eGFR 15–29 mL/min/1.73m²) with Insulin Dependence
- •Severe Hypoglycemia Unawareness
Quick Selection Guide
- •<45 years, BMI ≥35, HbA1c >9.5%: Prioritize metabolic surgery ($5,800–$8,200) — highest durable remission rate.
- •65+ years, limited budget (<$500/year), mild hyperglycemia (HbA1c 7.0–8.0%): Start metformin + lifestyle coaching ($12–$22 + $135–$210) — cost-effective, low-risk.
- •T2DM + eGFR 25–35 mL/min: Avoid metformin; use GLP-1 RA ($1,180–$1,520/year) — renal protective, weight-neutral.
- •Frequent severe hypoglycemia on basal-bolus regimen: Add professional CGM ($260–$390) — reduces events by >50%.
- •Newly diagnosed, HbA1c 6.5–7.5%: Lifestyle intervention + metformin ($12–$22/year) — optimal first-line value.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Diabetes mellitus Medical Vacation Packages
Curated transparent all-inclusive packages combining Diabetes mellitus treatment with China top medical destinations:
